CA2462966A1 - Factor viii c2 domain variants - Google Patents

Factor viii c2 domain variants Download PDF

Info

Publication number
CA2462966A1
CA2462966A1 CA002462966A CA2462966A CA2462966A1 CA 2462966 A1 CA2462966 A1 CA 2462966A1 CA 002462966 A CA002462966 A CA 002462966A CA 2462966 A CA2462966 A CA 2462966A CA 2462966 A1 CA2462966 A1 CA 2462966A1
Authority
CA
Canada
Prior art keywords
factor viii
ser
leu
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002462966A
Other languages
English (en)
French (fr)
Inventor
John S. Lollar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2462966A1 publication Critical patent/CA2462966A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002462966A 2001-11-30 2002-11-27 Factor viii c2 domain variants Abandoned CA2462966A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33456901P 2001-11-30 2001-11-30
US60/334,569 2001-11-30
PCT/US2002/037884 WO2003047507A2 (en) 2001-11-30 2002-11-27 Factor viii c2 domain variants

Publications (1)

Publication Number Publication Date
CA2462966A1 true CA2462966A1 (en) 2003-06-12

Family

ID=23307813

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002462966A Abandoned CA2462966A1 (en) 2001-11-30 2002-11-27 Factor viii c2 domain variants

Country Status (8)

Country Link
US (1) US20040249134A1 (enExample)
EP (1) EP1456235A4 (enExample)
JP (1) JP2005511038A (enExample)
CN (1) CN1630666A (enExample)
AU (1) AU2002364509A1 (enExample)
CA (1) CA2462966A1 (enExample)
MX (1) MXPA04005079A (enExample)
WO (1) WO2003047507A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
PL1750733T3 (pl) * 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
MY185597A (en) * 2005-09-20 2021-05-24 Avantor Performance Mat Inc Vegetarian protein a preparation and methods thereof
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
IT1394522B1 (it) 2009-01-09 2012-07-05 Invatec Technology Ct Gmbh Dispositivo medicale con rilascio di farmaco
CA2780763A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
CN104788557A (zh) * 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
BR112013011041B1 (pt) 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
EP3107561A4 (en) * 2014-02-19 2017-12-20 Bloodworks Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
WO2025164792A1 (ja) * 2024-02-02 2025-08-07 学校法人自治医科大学 高比活性/高分泌発現型の第viii因子改変体、高発現型の第viii因子コード核酸及びそれらの用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
MX9203440A (es) * 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) * 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej

Also Published As

Publication number Publication date
MXPA04005079A (es) 2004-08-19
AU2002364509A1 (en) 2003-06-17
CN1630666A (zh) 2005-06-22
JP2005511038A (ja) 2005-04-28
WO2003047507A3 (en) 2003-07-17
WO2003047507A2 (en) 2003-06-12
US20040249134A1 (en) 2004-12-09
EP1456235A4 (en) 2005-08-17
EP1456235A2 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
CA2374675C (en) Modified factor viii
AU693837B2 (en) Hybrid human/animal factor VIII
AU717686B2 (en) Modified factor VIII
AU682147B2 (en) Hybrid human/porcine factor VIII
KR100490612B1 (ko) 변형된 인자 ⅷ
US6770744B2 (en) Modified factor VIII
US20030068785A1 (en) Modified factor VIII
JP4361786B2 (ja) 操作されたジスルフィド結合を有する安定化蛋白質
US20040249134A1 (en) Factor viii c2 domain variants
US20040005670A1 (en) Compositions and methods for the treatment of hemophilia A

Legal Events

Date Code Title Description
FZDE Discontinued